Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of calcipotriene.
Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Calcium acetate | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium acetate. |
| Calcium glucoheptonate | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium glucoheptonate. |
| Calcium chloride | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium chloride. |
| Calcium | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium. |
| Calcium carbonate | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium carbonate. |
| Calcium citrate | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium citrate. |
| Calcium gluconate | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium gluconate. |
| Calcium Phosphate | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium Phosphate. |
| Calcium glubionate anhydrous | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium glubionate anhydrous. |
| Calcium lactate | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium lactate. |
| Calcium lactate gluconate | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium lactate gluconate. |
| Calcium pangamate | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium pangamate. |
| Calcium levulinate | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium levulinate. |
| Calcium cation | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium cation. |
| Calcium polycarbophil | The risk or severity of adverse effects can be increased when Calcipotriol is combined with Calcium polycarbophil. |
| Phenytoin | The serum concentration of Calcipotriol can be decreased when it is combined with Phenytoin. |
| Fosphenytoin | The serum concentration of Calcipotriol can be decreased when it is combined with Fosphenytoin. |